Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer
- 2k Downloads
Targeted therapy against triple-negative breast cancers, which lack expression of the estrogen, progesterone, and HER2 receptors, is not available and the overall response to cytotoxic chemotherapy is poor. One of the molecular hallmarks of triple-negative breast cancers is increased expression of genes that are transcriptionally activated by hypoxia-inducible factors (HIFs), which are implicated in many critical aspects of cancer progression including metabolism, angiogenesis, invasion, metastasis, and stem cell maintenance. Ganetespib is a second-generation inhibitor of heat shock protein 90 (HSP90), a molecular chaperone that is essential for the stability and function of multiple client proteins in cancer cells including HIF-1α. In this study, human MDA-MB-231 and MDA-MB-435 triple-negative breast cancer cells were injected into the mammary fat pad of immunodeficient mice that received weekly intravenous injections of ganetespib or vehicle following the development of palpable tumors. Ganetespib treatment markedly impaired primary tumor growth and vascularization, and eliminated local tissue invasion and distant metastasis to regional lymph nodes and lungs. Ganetespib treatment also significantly reduced the number of Aldefluor-positive cancer stem cells in the primary tumor. Primary tumors of ganetespib-treated mice had significantly reduced levels of HIF-1α (but not HIF-2α) protein and of HIF-1 target gene mRNAs encoding proteins that play key roles in angiogenesis, metabolism, invasion, and metastasis, thereby providing a molecular basis for observed effects of the drug on the growth and metastasis of triple-negative breast cancer.
Triple-negative breast cancers (TNBCs) respond poorly to available chemotherapy.
TNBCs overexpress genes regulated by hypoxia-inducible factors (HIFs).
Ganetespib induces degradation of HSP90 client proteins, including HIF-1α.
Ganetespib inhibited TNBC orthotopic tumor growth, invasion, and metastasis.
Ganetespib inhibited expression of HIF-1 target genes involved in TNBC progression.
KeywordsHypoxia-inducible factor 1 Ganetespib Hsp90 inhibitor Breast cancer metastasis Cancer stem cell
We thank Karen Padgett (Novus Biologicals) for providing antibodies against HIF-1β, HIF-2α, Ki67, and P4HA1. This work was supported in part by a sponsored research agreement with Synta Pharmaceuticals Corp., which provided ganetespib and vehicle but had no involvement in the experimental design, data analysis, or manuscript preparation.
G.L.S. is the C. Michael Armstrong Professor at the Johns Hopkins University School of Medicine and an American Cancer Society Research Professor. L.X., D.M.G., and W.L. were supported by grants from the Chinese Scholarship Council, Susan G. Komen Foundation, and National Cancer Institute (K99-CA168746), respectively. All authors confirm that there is no conflict of interest associated with this publication.
- 11.Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B, Winnard PT Jr et al (2012) HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31:1757–1770PubMedCentralPubMedCrossRefGoogle Scholar
- 22.Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y et al (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 106:8368–8373PubMedCentralPubMedCrossRefGoogle Scholar
- 24.Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, Proia DA (2013) Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs 2013 May 18 [Epub ahead of print]Google Scholar
- 25.Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J et al (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11:475–484PubMedCrossRefGoogle Scholar
- 26.Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li Y et al (2012) Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 18:4973–4985PubMedCentralPubMedCrossRefGoogle Scholar
- 27.Schito L, Rey S, Tafani M, Zhang H, Wong CC, Russo A, Russo MA, Semenza GL (2012) Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci U S A 109:E2707–E2716PubMedCentralPubMedCrossRefGoogle Scholar
- 33.Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J et al (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69:1302–1313PubMedCentralPubMedCrossRefGoogle Scholar